Dr Mary Lou Chatterton

Link-me: protocol for a randomised controlled trial of a systematic approach to stepped mental health care in primary care

Susan Fletcher, Patty Chondros, Victoria Palmer, Mary Chatterton, Matthew Spittal, Cathrine Mihalopoulos, Anna Wood, Meredith Harris, Philip Burgess, Bridget Bassilios, Jane Pirkis, Jane Gunn

(2019), Vol. 78, pp. 63-75, Contemporary clinical trials, Amsterdam, The Netherlands, C1

Economic evaluation of stepped care for the management of childhood anxiety disorders: results from a randomised trial

Mary Chatterton, Ronald Rapee, Max Catchpool, Heidi Lyneham, Viviana Wuthrich, Jennifer Hudson, Maria Kangas, Cathrine Mihalopoulos

(2019), pp. 1-10, Australian and New Zealand journal of psychiatry, London, Eng., C1

The economic costs of loneliness: a review of cost-of-illness and economic evaluation studies

Cathrine Mihalopoulos, Long Le, Mary Chatterton, Jessica Bucholc, Julianne Holt-Lunstad, Michelle Lim, Lidia Engel

(2019), pp. 1-14, Social psychiatry and psychiatric epidemiology, Berlin, Germany, C1

Health state utility values of high prevalence mental disorders in Australia: results from the National Survey of Mental Health and Wellbeing

Cathrine Mihalopoulos, Lidia Engel, Long Le, Anne Magnus, Meredith Harris, Mary Chatterton

(2018), Vol. 27, pp. 1815-1825, Quality of life research, Dordrecht, The Netherlands, C1

Economic evaluation of a dietary intervention for adults with major depression (the "SMILES" trial)

Mary Chatterton, Cathrine Mihalopoulos, Adrienne O'Neil, Catherine Itsiopoulos, Rachelle Opie, David Castle, Sarah Dash, Laima Brazionis, Michael Berk, Felice Jacka

(2018), Vol. 18, BMC public health, London, Eng., C1

Mental health consultations in the perinatal period: a cost-analysis of Medicare services provided to women during a period of intense mental health reform in Australia

G Chambers, S Randall, C Mihalopoulos, N Reilly, E Sullivan, N Highet, V Morgan, M Croft, M Chatterton, M Austin

(2018), Vol. 42, pp. 514-521, Australian health review, Clayton, Vic., C1

Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial

Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Seetal Dodd, Alyna Turner, Ellie Brown, Felice Jacka, Susan Cotton, Jon-Paul Khoo, Mary Chatterton, Bianca Kavanagh, Sarah Nadjidai, Samantha Lo Monaco, Brian Harvey, Jerome Sarris, Gin Malhi, Nathan Dowling, Olivia Dean

(2018), pp. 1-9, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

Evaluating the long-term effectiveness of school-based depression, anxiety, and substance use prevention into young adulthood: protocol for the Climate School Combined study

Louise Birrell, Nicola Newton, Tim Slade, Catherine Chapman, Louise Mewton, Nyanda McBride, Leanne Hides, Mary Chatterton, Steve Allsop, Annalise Healy, Marius Mather, Catherine Quinn, Cathrine Mihalopoulos, Maree Teesson

(2018), Vol. 7, pp. 1-13, JMIR research protocols, Toronto, Ont., C1

Policy impacts of the Australian National Perinatal Depression Initiative: psychiatric admission in the first postnatal year

Wang-Sheng Lee, Cathrine Mihalopoulos, Mary Chatterton, Georgina Chambers, Nicole Highet, Vera Morgan, Elizabeth Sullivan, Marie-Paule Austin

(2018), pp. 1-11, Administration and policy in mental health and mental health services research, New York, N.Y., C1

A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial)

F Jacka, A O'Neil, R Opie, C Itsiopoulos, S Cotton, M Mohebbi, D Castle, S Dash, C Mihalopoulos, M Chatterton, L Brazionis, O Dean, A Hodge, M Berk

(2017), Vol. 15, pp. 1-13, BMC medicine, London, Eng., C1

Psychosocial therapies for the adjunctive treatment of bipolar disorder in adults: network meta-analysis

M Chatterton, E Stockings, M Berk, J Barendregt, R Carter, C Mihalopoulos

(2017), Vol. 210, pp. 333-341, British journal of psychiatry, London, Eng., C1

Cost of high prevalence mental disorders: findings from the 2007 Australian National Survey of Mental Health and Wellbeing

Y-C Lee, M Chatterton, A Magnus, M Mohebbi, L Le, C Mihalopoulos

(2017), Vol. 51, pp. 1198-1211, Australian and New Zealand journal of psychiatry, London, Eng., C1

Economic evaluation of a psychological intervention for high distress cancer patients and carers: costs and quality-adjusted life years

M Chatterton, S Chambers, S Occhipinti, A Girgis, J Dunn, R Carter, S Shih, C Mihalopoulos

(2016), Vol. 25, pp. 857-864, Psycho-oncology, Chichester, Eng., C1

Economic evaluations of interventions designed to prevent mental disorders: a systematic review

C Mihalopoulos, M Chatterton

(2015), Vol. 9, pp. 85-95, Early intervention in psychiatry, London, Eng., C1

The population cost-effectiveness of a parenting intervention designed to prevent anxiety disorders in children

C Mihalopoulos, T Vos, R Rapee, J Pirkis, M Chatterton, Y Lee, R Carter

(2015), Vol. 56, pp. 1026-1033, Journal of child psychology and psychiatry, Chichester, Eng., C1

A randomised, controlled trial of a dietary intervention for adults with major depression (the 'SMILES' trial): study protocol

A O'Neil, M Berk, C Itsiopoulos, D Castle, R Opie, J Pizzinga, L Brazionis, A Hodge, C Mihalopoulos, M Chatterton, O Dean, F Jacka

(2013), Vol. 13, pp. 1-7, BMC psychiatry, London, England, C1

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode

M Ekman, P Lindgren, C Miltenburger, G Meier, J Locklear, M Chatterton

(2012), Vol. 30, pp. 513-531, PharmacoEconomics, Dordrecht, The Netherlands, C1-1

Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder : a meta-analysis of randomized controlled trials

E Vieta, O G�nther, J Locklear, M Ekman, C Miltenburger, M Chatterton, M �str�m, B Paulsson

(2011), Vol. 14, pp. 1029-1049, International journal of neuropsychopharmacology, Cambridge, England, C1-1

Treatment options for bipolar depression : a systematic review of randomized, controlled trials

E Vieta, J Locklear, O G�nther, M Ekman, C Miltenburger, M Chatterton, M �str�m, B Paulsson

(2010), Vol. 30, pp. 579-590, Journal of clinical psychopharmacology, Philadelphia, Pa., C1-1

Impact of bipolar disorder on the family : utilization and cost of health care resources

M Chatterton, X Ke, B Lewis, K Rajagopalan, A Lazarus

(2008), Vol. 33, pp. 15-34, P and T, Yardley, Pa., C1-1

Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review

R Fleurence, M Chatterton, J Dixon, K Rajagopalan

(2007), Vol. 9, pp. 419-428, Primary care companion to the journal of clinical psychiatry, Memphis, TN, C1-1

The family impact and costs of migraine

P Stang, W Crown, R Bizier, M Chatterton, R White

(2004), Vol. 10, pp. 313-320, American journal of managed care, Plainsboro, NJ, C1-1

Reliability and validity of the Migraine Therapy Assessment Questionnaire

M Chatterton, J Lofland, A Shechter, W Curtice, X Hu, J Lenow, S Smullens, D Nash, S Silberstein

(2002), Vol. 42, pp. 1006-1015, Headache, Hoboken, N. J., C1-1

Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine

J Lofland, S Kim, A Batenhorst, N Johnson, M Chatterton, R Cady, R Kaniecki, D Nash

(2001), Vol. 76, pp. 1093-1101, Mayo Clinic proceedings, New York, N. Y., C1-1

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis

J Lofland, S Touch, J O'Connor, M Chatterton, E Moxey, L Paddock, D Nash, S Desai

(2000), Vol. 22, pp. 1357-1369, Clinical therapeutics, Bridgewater, N. J., C1-1

Development and validation of a questionnaire to evaluate patient satisfaction with diabetes disease management

L Paddock, J Veloski, M Chatterton, F Gevirtz, D Nash

(2000), Vol. 23, pp. 951-956, Diabetes care, Alexandria, VA, C1-1

Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection

M Chatterton, J Scott-Lennox, A Wu, J Scott

(1999), Vol. 15, pp. 67-74, PharmacoEconomics, Auckland, N. Z., C1-1